These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21788466)

  • 41. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
    HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM; Donnell D; Ndase P; Mugo NR; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kakia A; Odoyo J; Mucunguzi A; Nakku-Joloba E; Twesigye R; Ngure K; Apaka C; Tamooh H; Gabona F; Mujugira A; Panteleeff D; Thomas KK; Kidoguchi L; Krows M; Revall J; Morrison S; Haugen H; Emmanuel-Ogier M; Ondrejcek L; Coombs RW; Frenkel L; Hendrix C; Bumpus NN; Bangsberg D; Haberer JE; Stevens WS; Lingappa JR; Celum C;
    N Engl J Med; 2012 Aug; 367(5):399-410. PubMed ID: 22784037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
    Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
    AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
    Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
    Weberschock T; Gholam P; Hueter E; Flux K; ; Hartmann M
    Eur J Med Res; 2009; 14(12):516-9. PubMed ID: 20149984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
    D'Avolio A; Sciandra M; Siccardi M; Baietto L; Gonzalez de Requena D; Bonora S; Di Perri G
    J Chromatogr Sci; 2008 Jul; 46(6):524-8. PubMed ID: 18647474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
    Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
    Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
    Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
    PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
    Lyseng-Williamson KA; Scott LJ
    Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV preexposure prophylaxis in the real world.
    Daskalakis DC
    Top Antivir Med; 2014; 22(4):670-5. PubMed ID: 25398067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.